Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial.

Ruth M de TuteCurly T C M Morris David A CairnsJulia M BrownJamie CavenaghA John AshcroftJohn A SnowdenKwee YongEleni TholouliMatthew JennerAnna HockadayMark T DraysonTreen C M MorrisAndy C RawstronRoger G Owen

Published in: Bone marrow transplantation (2024)

Keyphrases

stem cell transplantation
multiple myeloma
high dose
newly diagnosed
study protocol
phase iii
bone marrow
acute lymphoblastic leukemia
clinical trial
acute myeloid leukemia
phase ii
cell therapy
hodgkin lymphoma
low dose
platelet rich plasma
randomized controlled trial
stem cells
mesenchymal stem cells